Cellectar Biosciences To Present at SeeThru Equity and Dawson James Investor Conferences Oct 11, 2016
Cellectar Biosciences Announces Enrollment of First Patient into Third Cohort of Its Phase I Clinical Study of CLR 131 in Multiple Myeloma Oct 6, 2016
Cellectar Biosciences Announces New Positive Data from Phase I Clinical Study of CLR 131 in Multiple Myeloma Sep 29, 2016
Cellectar Biosciences Announces Lead Compound CLR 131 To Be Studied In Head and Neck Cancer in $12M University of Wisconsin SPORE Grant Sep 12, 2016
Cellectar Biosciences To Present at the 18th Annual Rodman & Renshaw Global Investment Conference Sep 6, 2016
UPDATE -- Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results Aug 12, 2016
Cellectar Biosciences Announces Recent Key Accomplishments and Second Quarter 2016 Financial Results Aug 11, 2016